Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s scientific advisory board, discussed the changing lymphoma treatment landscape and highlighted potentially game changing treatments.
Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s scientific advisory board, discussed the changing lymphoma treatment landscape and highlighted potentially game changing treatments.
Transcript
Immunotherapies have been moving to earlier lines of therapy, both alone and in combination with chemotherapy. How might these treatment options and sequencing for lymphomas evolve in the near future based on the current landscape and pipeline?
I think we know that these—the bispecifics in particular—are very combinable, and they're very active. So I think we will begin to see these being used more and more in clinical trials upfront in indolent lymphomas and then combining them with chemoimmunotherapy in aggressive lymphomas. I think that in Hodgkin lymphoma, we are likely, I didn't mention that before, but I think we're likely to see hopefully a publication from the S1826 trial comparing brentuximab plus AVD [doxorubicin, vinblastine, and dacarbazine] to nivolumab plus AVD, and I think this is going to be a major game changer and change how we initially treat patients. So I think, you know, the goal here is to have long-term remissions in as many patients as possible up front, and then continue to develop drugs for those patients who fail, but it's really a very exciting space.
As we begin to see more longer-term data on newer generation BTK inhibitors, including data in CLL presented at ASH 2023, how do you see this area evolving in the near future?
We've really seen in the past year or 2, particularly in the US, we're not really using ibrutinib anymore. I mean, this was a real game changing drug that changed the prognosis of CLL. It was really dramatic when we first started using this drug, but we now know the next generations are better tolerated and very active. So now I think the question is the noncovalent BTK inhibitors like pirtobrutinib, which have even more favorable toxicity profiles than the the approved BTK inhibitors. So I think it's going to be very interesting to see how they compare in previously untreated patients, to know whether maybe we're going to be going to these noncovalent ones, as our initial frontline therapy—but we have some work to do is to compare those and really look at the data. But I think, overall, there's just been such incredible changes in how we manage this disease, I think maybe of any of the diseases we treat from when I started as a fellow and we were using chemoimmunotherapy and patients really didn't do well and had a lot of toxicity. And now, I think chemoimmunotherapy is very rarely even considered in CLL, even in our most favorable young patients who are mutated.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More